A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block?

Lupus

Volumn 21, Issue 6, 2012, Pages 666-671

  Ruffatti, A ^a   Milanesi, O ^a   Chiandetti, L ^a   Cerutti, A ^a   Gervasi, M T ^b   De Silvestro, G ^b   Pengo, V ^a   Punzi, L ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cardiovascular diseases; congenital heart block; neonatal lupus; pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; BETAMETHASONE; IMMUNOGLOBULIN; LA ANTIBODY; RO ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CESAREAN SECTION; CONGENITAL HEART BLOCK; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MEDICAL HISTORY; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL;

ADULT; ANTIBODIES, ANTINUCLEAR; BETAMETHASONE; COMBINED MODALITY THERAPY; FEMALE; HEART BLOCK; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; PLASMAPHERESIS; PREGNANCY; RECURRENCE; TREATMENT OUTCOME;

EID: 84859894402     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311430969     Document Type: Article

References (11)

1. Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009 ; 103: 1102-1106
2. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum. 1999 ; 42: 2335-2345
3. Ruffatti A, Favaro M, Cozzi F, et al. Anti-SSA/Ro-related congenital heart block in two family members of different generations. [letter]. Arthritis Rheum. 2005 ; 52: 1623-1625
4. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010 ; 62: 138-146
5. David AL, Ataullah I, Yates R, Sullivan I, Charles P, Williams D. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. Obstet Gynecol. 2010 ; 116 (Suppl. 2). 543-547
6. Brucato A, Ramoni V, Gerosa M, Pisoni MP. Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin [letter]. Obstet Gynecol. 2011 ; 117: 177-177
7. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010 ; 62: 1147-1152
8. Ruffatti A, Marson P, Pengo V, et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev. 2007 ; 6: 196-202
9. Ostensen M. Intravenous immunoglobulin does not prevent recurrence of congenital heart block in children of SSA/Ro-positive mothers [editorial]. Arthritis Rheum. 2010 ; 62: 911-914
10. Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus. 2002 ; 11: 145-151
11. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009 ;: CD001146 - CD001146